The demographical and clinical characteristics of subjects at baseline. by Soheila Qanbari (20455173)

Subjects:

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

The Human Disharmony Loop Clinical Presentation. by James M. Friedman (22522150)

Subjects:

Statistically significant linear decrease in use of antidepressants, antipsychotics, psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics during the observed time period. by Jelena Filimonovic (22305307)

The values of angiotensin II by Ningning Wang (560944)

Subjects:

Spearman correlation matrix analysis of the RAAS system and glucose metabolism indexes in hypertensive (A) and normotensive (B) patients. by Ningning Wang (560944)

Subjects:

Spearman correlation matrix analysis of the RAAS system and glucose metabolism indexes at different hypertension subgroups. by Ningning Wang (560944)

Subjects:

Spearman correlation matrix analysis of the RAAS system and glucose metabolism indexes at different normotension subgroups. by Ningning Wang (560944)

Subjects:

Significantly decreased necrosis observed on wheat leaves inoculated with <i>ΔZtknr4</i>. by Erika Kroll (20537020)

S1 Dataset - by Na Wang (193263)

Subjects:

ROBINS-I assessments. by Martha R. Smith (20410184)

Subjects:

Results of the linear models for the amplitudes (in <i>μ</i>V) of the components P1, N1, P2, and N400. by Elena Bolt (20396190)

Multiple linear regression analysis of the RAAS and glucose metabolism indicators before and after treatment in DKD and non-DKD patients. by Ningning Wang (560944)

Subjects:

Comparison of serum VEGF-A165 concentrations pre-bevacizumab administration in patients with increased VEGF-A post-bevacizumab administration and those with decreased VEGF-A. by Masashi Okawa (8951294)

Subjects:

Statistically significant linear increase in use of antidementia medications and antipsychotics during the observed time period. by Jelena Filimonovic (22305307)

S1 Data - by Kazuyoshi Ohkawa (836847)

Subjects:

IFA significantly attenuated capsule-mediated resistance to the binding of C3b and C5b-9 to bacterial surface. by Tingting Wang (123983)

Subjects:

HAstV-8 (D471S, N512D) spike has decreased or no binding to FcRn compared to wild-type HAstV-8 spike. by Catalina Aguilera-Flores (21743843)

Clinical characteristics at baseline and at the end of the study. by Naruyoshi Gyoutoku (22537831)

Subjects: